Literature DB >> 1816181

Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics.

G Bonfiglio1, D M Livermore.   

Abstract

The susceptibility of Xanthomonas maltophilia strains to beta-lactams was shown to depend on the concentrations at which individual media were prepared. MIC and disc susceptibility tests were performed on solidified Mueller-Hinton and Iso-Sensitest media prepared at 0.1, 0.3, 1, and 3 x the concentrations recommended by the manufacturers. Nine of ten X. maltophilia strains tested showed increasing sensitivity to meropenem, cefotaxime, cefoperazone, piperacillin and latamoxef as the nutrient concentrations of the two media were increased. The opposite pattern was found with one strain (NCTC 10257) on Mueller-Hinton agar. This strain behaved inconsistently on Iso-Sensitest agar. Previous studies have shown that medium-dependent susceptibility in X. maltophilia is not related to beta-lactamase expression. The present study demonstrated that 22 and 25 kDa outer membrane proteins were induced on media with higher nutrient concentrations. The possible relationship of these proteins to sensitivity is considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1816181     DOI: 10.1093/jac/28.6.837

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

Authors:  J L Muñoz; M I García; S Muñoz; S Leal; M Fajardo; J A Garćia-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

Review 3.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 4.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

5.  Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.

Authors:  G A Pankuch; M R Jacobs; S F Rittenhouse; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 7.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

8.  In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  C D Poulos; S O Matsumura; B M Willey; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

9.  Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia.

Authors:  Ayesha Khan; Cesar A Arias; April Abbott; Jennifer Dien Bard; Micah M Bhatti; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

10.  Selective pressure of antibiotic pollution on bacteria of importance to public health.

Authors:  Alfredo Tello; Brian Austin; Trevor C Telfer
Journal:  Environ Health Perspect       Date:  2012-05-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.